China Resources Pharmaceutical Subsidiary Tasly Posts Higher Profit on Lower RevenueTip Ranks·Oct 23, 2026 at 10:40 AM03320-1.79%600535+0.14%
China Resources Pharmaceutical subsidiary Tasly Pharmaceutical’s nine-month net profit rises to RMB 1.09 billionPUBT·Oct 23, 2026 at 10:07 AM600535+0.14%
Asian Stocks That May Be Priced Below Intrinsic Estimates In October 2026Simplywall·Oct 4, 2026 at 11:18 PM600483+2.55%600535+0.14%
Tianjin Development FY26 H1 profit attributable to owners falls 5.58% to HK$ 325.22 million; revenue slips 3.53% to HK$ 1.66 billionPUBT·Aug 28, 2026 at 09:44 AM00882-0.77%600535+0.14%
Tasly Delivers Profit Growth on Flat Revenue, Bolstering China Resources PharmaceuticalTip Ranks·Jul 14, 2026 at 12:08 PM03320-1.79%600535+0.14%
Heart Drug Sales Soar in China After Education Guru Zhang Xuefeng Dies SuddenlyYicai·Mar 27, 2026 at 12:20 PM600535+0.14%
CHINARES PHARMA subsidiary TASLY earned 1.105 billion RMB for the year, an increase of 15.6%AASTOCKS·Mar 19, 2026 at 02:32 PM513700-2.59%513060-2.55%
China Resources Pharmaceutical's subsidiary TASLY earned 1.105 billion RMB last year, an increase of 15.7%AASTOCKS·Feb 8, 2026 at 10:35 AM600535+0.14%159929-0.99%
With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibitedWallstreetcn·Jan 27, 2026 at 10:41 AM512290-1.79%159929-0.99%
19:00 ET Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standardprnewswire·Jan 26, 2026 at 12:03 AM600535+0.14%
Tasly Pharmaceutical’s Nine-Month Financials Show Increased ProfitTip Ranks·Oct 24, 2025 at 09:42 AM600535+0.14%
TASLY: The net profit for the third quarter was 210 million yuan, a year-on-year increase of 16.56%Zhitong·Oct 24, 2025 at 08:59 AM600535+0.14%
TASLY: The company's medicine Wenjing Decoction Granules has obtained a drug registration certificateZhitong·Oct 13, 2025 at 09:12 AM600535+0.14%
